42 results
424B5
QNTM
Quantum BioPharma Ltd
16 Feb 24
Prospectus supplement for primary offering
6:36pm
$326,991
2. Chronic Toxicity to initiate phase-2 (3-month study)
Study design for 2-species toxicity trial
US$37,158
Involves cost associated … 2. Estimate based on industry standard costs.
Chronic tox studies to complete phase-2 (2 species, up to 9 months)
US$2,601,070
Requirement
F-3
QNTM
Quantum BioPharma Ltd
22 Dec 23
Shelf registration (foreign)
6:49pm
contractual estimates.
Sub-total
US$326,991
2. Chronic Toxicity to initiate phase-2 (3-month study)
Study design for 2-species toxicity trial
US$37,158
Involves … $111,474
Studies warranted by regulatory agencies before the start of Phase 2. Estimate based on industry standard costs.
Chronic tox studies
6-K
EX-99.2
QNTM
Quantum BioPharma Ltd
20 Jul 23
Condensed consolidated interim financial statements
5:05pm
certain proprietary formulations of PEA owned by Epitech and that are to be used to treat chronic kidney disease in humans or, if a prescription drug … , any other human condition that is related to pain and chronic pain. In addition, under the terms of the Epitech License, as further amended on July 9
6-K
EX-99.2
QNTM
Quantum BioPharma Ltd
12 May 23
Condensed consolidated interim financial statements
6:55pm
of PEA owned by Epitech and that are to be used to treat chronic kidney disease in humans or, if a prescription drug, any other human condition … that is related to pain and chronic pain. In addition, under the terms of the Epitech License, as further amended on July 9, 2020, if Epitech develops
6-K
EX-99.1
w3u69ecrhg5jpdpo3
17 Apr 23
FSD Pharma Inc. 6-K
9:34am
6-K
EX-99.2
uf3e6j9pgran03
14 Nov 22
Condensed consolidated interim financial statements
6:02am
6-K
EX-99.1
kztvatghau67t09aae
12 Sep 22
FSD Pharma Inc. 6-K
8:42am
6-K
EX-99.1
g5xp88mrqhct
6 Sep 22
FSD Pharma Inc. 6-K
8:33am
6-K
EX-99.2
wd0 pm20q8l38mn8
12 Aug 22
Condensed consolidated interim financial statements
4:58pm
6-K
EX-99.2
9ycv04f0
13 May 22
Condensed consolidated interim financial statements
5:10pm
20-F
9zpq4iuyimx68128y
31 Mar 22
Annual report (foreign)
8:09am
20-F
EX-15.1
1yvdxoszn2
31 Mar 22
Annual report (foreign)
8:09am
20-F
EX-4.5
8qn3o3nu
31 Mar 22
Annual report (foreign)
8:09am
6-K
EX-99.1
8oe9myncbhr
12 Nov 21
Management's Discussion and Analysis of Financial Condition and Results of
9:48pm
6-K
EX-99.1
jg3p2 z6mb0pwgdxs
12 Aug 21
Management's Discussion and Analysis of Financial Condition and Results of
9:53pm
6-K
EX-99.2
fasrr0 5z2lnlsc9
7 May 21
Condensed consolidated interim financial statements
4:38pm
40-F
EX-99.1
ipsd2e
17 Mar 21
Annual report (Canada)
12:00am